Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC

Clinical trial NCT04765709 · TERMINATED

Trial details

NCT number: NCT04765709
Sponsor: Mario Negri Institute for Pharmacological Research
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Stage III

Start date: 2021-09-24
Primary completion: 2025-01-30
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.